12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LibiGel testosterone: Completed Phase III enrollment

BioSante completed enrollment of over 500 surgically menopausal women in the first of 2 double-blind, placebo-controlled, U.S. and Canadian Phase III trials evaluating transdermal LibiGel. BioSante expects to complete enrollment of about 500 patients in...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >